Multiple Sclerosis CD56+ NK Cells

Multiple Sclerosis CD56+ NK Cells for Autoimmune Demyelination Research

Multiple Sclerosis CD56+ NK Cells are isolated from the peripheral blood of IRB-consented adult donors with a clinically confirmed diagnosis of multiple sclerosis and cryopreserved in CryoStor® CS10 within 24 hours of collection. These CD56+ CD3− natural killer cells provide a purified innate lymphocyte population for investigating immune regulation and cytotoxicity in autoimmune demyelinating disease.

NK Cell Biology in Multiple Sclerosis

Multiple sclerosis is an autoimmune demyelinating disease of the central nervous system in which autoreactive lymphocytes cross the blood-brain barrier and drive inflammatory injury to myelin and axons. NK cells occupy an unusual position in that process: rather than acting only as effectors, they appear to help restrain the autoreactive adaptive response, which is why they are a target of interest rather than simply a bystander population.

• Human NK cells divide into a cytotoxic CD56^dim majority and an immunoregulatory CD56^bright subset; the CD56^bright compartment is the one most consistently implicated in multiple sclerosis.
• CD56^bright NK cells can suppress activated autologous T cells, providing a mechanistic link between innate lymphocyte function and control of autoreactive T cell expansion.
• Expansion of the CD56^bright subset is an established pharmacodynamic effect of certain multiple sclerosis therapeutics, making NK phenotype a clinically anchored readout rather than a purely exploratory one.
• NK activating and inhibitory receptor repertoires, including NKG2A, NKG2D and the killer-cell immunoglobulin-like receptors, shape cytotoxic potential and interaction with HLA ligands.
• Disease-modifying therapies differ substantially in their effects on NK number and function, so treatment-annotated donors are essential to interpretable studies.
• A purified CD56+ preparation permits direct cytotoxicity, degranulation and cytokine assays that cannot be resolved cleanly from a mixed mononuclear fraction.

Donor Stratification Available

• Disease course: relapsing-remitting, secondary progressive, or primary progressive
• Clinical state at collection: active relapse vs clinical stability where documented
• Disease duration and age at onset
• Disease-modifying therapy class, or treatment-naive
• Disability status where documented
• Demographics: age, sex assigned at birth, race/ethnicity
• Matched healthy controls available

Product Features

• Research Use Only (RUO), CD56+ enriched NK cells
• Isolated from clinically diagnosed multiple sclerosis donors
• High viability and enrichment; purity and viability reported per lot
• Cryopreserved in CryoStor® CS10 media
• Processed within 24 hours of collection
• Standard or custom aliquot sizes; cell numbers reported per lot
• Ethically sourced with IRB approval and HIPAA compliance

De-identified Donor Data

• Confirmed diagnosis of multiple sclerosis and disease course
• Demographics: age, sex assigned at birth, race/ethnicity
• Self-reported clinical history and medication use, including disease-modifying therapy
• Additional multiple sclerosis-specific metadata available on request

Applications

• NK cell subset phenotyping, including CD56^bright and CD56^dim distribution
• NK-mediated suppression of autologous activated T cells
• Cytotoxicity, degranulation and cytokine secretion assays
• Activating and inhibitory receptor repertoire characterisation
• Single-cell RNA sequencing of innate lymphocyte populations
• Pharmacodynamic profiling of disease-modifying therapy effects on NK cells
• Target validation for NK-directed immunomodulatory candidates
• Biomarker discovery in autoimmune demyelination

Other Multiple Sclerosis Specimen Types

• Multiple Sclerosis CD3+ T Cells
• Multiple Sclerosis CD4+ T Cells
• Multiple Sclerosis CD8+ T Cells
• Multiple Sclerosis CD19+ B Cells
• Multiple Sclerosis PBMC
• Multiple Sclerosis Leukopak
• Multiple Sclerosis Plasma
• Multiple Sclerosis Serum
• Multiple Sclerosis Whole Blood
• Multiple Sclerosis Cerebrospinal Fluid

Compliance and Quality Assurance

• IRB-approved collection and 21 CFR Part 11-compliant e-consent
• Standardised processing and quality protocols
• HIPAA-compliant data handling
• Documentation support available for regulatory review

Ordering & Customization

Multiple Sclerosis CD56+ NK Cells are offered in standard or custom aliquot sizes. For pricing, current availability, regulatory documentation or international support, contact learnmore@sanguinebio.com. To browse disease-state options and live stock status across our isolated NK cell inventory, visit our human CD56+ NK cells page.